CN102482265A - 用于治疗增殖性疾病的吡嗪基吡啶化合物 - Google Patents
用于治疗增殖性疾病的吡嗪基吡啶化合物 Download PDFInfo
- Publication number
- CN102482265A CN102482265A CN2010800392830A CN201080039283A CN102482265A CN 102482265 A CN102482265 A CN 102482265A CN 2010800392830 A CN2010800392830 A CN 2010800392830A CN 201080039283 A CN201080039283 A CN 201080039283A CN 102482265 A CN102482265 A CN 102482265A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- haloalkyl
- branched
- hydrogen
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- MCVYVLJMUWNABW-GFCCVEGCSA-N CC(C)(C)OC(N(CCC1)C[C@@H]1C(Nc(nc1)cc(-c2cncc(Cl)n2)c1Cl)=O)=O Chemical compound CC(C)(C)OC(N(CCC1)C[C@@H]1C(Nc(nc1)cc(-c2cncc(Cl)n2)c1Cl)=O)=O MCVYVLJMUWNABW-GFCCVEGCSA-N 0.000 description 1
- ROEIQMRIJIMZCL-LSLKUGRBSA-N CC(C)OC(CN(C1)C(OCc2ccccc2)=O)[C@H]1C(O)=O Chemical compound CC(C)OC(CN(C1)C(OCc2ccccc2)=O)[C@H]1C(O)=O ROEIQMRIJIMZCL-LSLKUGRBSA-N 0.000 description 1
- GOKDMAQJJCBKLR-UHFFFAOYSA-N ClC1=CN=CC(NCC2CCOCC2)=C[IH]1 Chemical compound ClC1=CN=CC(NCC2CCOCC2)=C[IH]1 GOKDMAQJJCBKLR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27593809P | 2009-09-04 | 2009-09-04 | |
| US61/275,938 | 2009-09-04 | ||
| US28496209P | 2009-12-28 | 2009-12-28 | |
| US61/284,962 | 2009-12-28 | ||
| PCT/EP2010/062881 WO2011026904A1 (en) | 2009-09-04 | 2010-09-02 | Pyrazinylpyridines useful for the treatment of proliferative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102482265A true CN102482265A (zh) | 2012-05-30 |
Family
ID=43480986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010800392830A Pending CN102482265A (zh) | 2009-09-04 | 2010-09-02 | 用于治疗增殖性疾病的吡嗪基吡啶化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20120165306A1 (enExample) |
| EP (1) | EP2473505A1 (enExample) |
| KR (1) | KR20120076352A (enExample) |
| CN (1) | CN102482265A (enExample) |
| AU (1) | AU2010291199A1 (enExample) |
| BR (1) | BR112012004836A2 (enExample) |
| CA (1) | CA2772265A1 (enExample) |
| IN (1) | IN2012DN01273A (enExample) |
| MX (1) | MX2012002758A (enExample) |
| WO (1) | WO2011026904A1 (enExample) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106795151A (zh) * | 2014-08-06 | 2017-05-31 | 诺华股份有限公司 | 蛋白激酶c抑制剂和它们的使用方法 |
| WO2021115335A1 (zh) * | 2019-12-09 | 2021-06-17 | 石药集团中奇制药技术（石家庄）有限公司 | 作为周期蛋白依赖性激酶9抑制剂的化合物及其应用 |
| CN115381823A (zh) * | 2021-05-24 | 2022-11-25 | 石药集团中奇制药技术（石家庄）有限公司 | 一种周期蛋白依赖性激酶9抑制剂的用途 |
| CN115381824A (zh) * | 2021-05-24 | 2022-11-25 | 石药集团中奇制药技术（石家庄）有限公司 | 周期蛋白依赖性激酶9抑制剂的用途 |
| CN115448874A (zh) * | 2021-06-09 | 2022-12-09 | 石药集团中奇制药技术（石家庄）有限公司 | 固体形式的周期蛋白依赖性激酶9抑制剂及其用途 |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8415381B2 (en) * | 2009-07-30 | 2013-04-09 | Novartis Ag | Heteroaryl compounds and their uses |
| WO2012101062A1 (en) * | 2011-01-28 | 2012-08-02 | Novartis Ag | Substituted bi-heteroaryl compounds as cdk9 inhibitors and their uses |
| WO2012101064A1 (en) * | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyrimidine biaryl compounds as protein kinase inhibitors |
| WO2014106606A1 (en) * | 2013-01-05 | 2014-07-10 | F. Hoffmann-La Roche Ag | Nove phenyl/pyridine series substitued by hydroxyethylamino for the treatment of cancer |
| CN105764887A (zh) | 2013-09-12 | 2016-07-13 | 住友化学株式会社 | 含氮饱和杂环化合物 |
| BR112019005526A2 (pt) | 2016-10-20 | 2019-06-18 | Pfizer | agentes antiproliferativos para tratamento de pah |
| WO2020016579A2 (en) | 2018-07-17 | 2020-01-23 | Gtn Ltd | Machine learning based methods of analysing drug-like molecules |
| GB202013419D0 (en) | 2020-08-27 | 2020-10-14 | Kuano Ltd | Transition state 2020 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| HK1054393B (en) * | 2000-09-20 | 2009-08-28 | Ortho-Mcneil Pharmaceutical, Inc. | Pyrazine derivatives as modulators of tyrosine kinases |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| AU2007336933A1 (en) * | 2006-12-22 | 2008-07-03 | Novartis Ag | Heteroaryl-heteroaryl compounds as CDK inhibitors for the treatment of cancer, inflammation and viral infections |
-
2010
- 2010-09-02 EP EP10748097A patent/EP2473505A1/en not_active Withdrawn
- 2010-09-02 KR KR1020127008621A patent/KR20120076352A/ko not_active Withdrawn
- 2010-09-02 CA CA2772265A patent/CA2772265A1/en not_active Abandoned
- 2010-09-02 BR BR112012004836A patent/BR112012004836A2/pt not_active IP Right Cessation
- 2010-09-02 AU AU2010291199A patent/AU2010291199A1/en not_active Abandoned
- 2010-09-02 CN CN2010800392830A patent/CN102482265A/zh active Pending
- 2010-09-02 WO PCT/EP2010/062881 patent/WO2011026904A1/en not_active Ceased
- 2010-09-02 MX MX2012002758A patent/MX2012002758A/es not_active Application Discontinuation
- 2010-09-02 US US13/393,457 patent/US20120165306A1/en not_active Abandoned
- 2010-09-02 IN IN1273DEN2012 patent/IN2012DN01273A/en unknown
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106795151A (zh) * | 2014-08-06 | 2017-05-31 | 诺华股份有限公司 | 蛋白激酶c抑制剂和它们的使用方法 |
| US10508101B2 (en) | 2014-08-06 | 2019-12-17 | Novartis Ag | Protein kinase C inhibitors and methods of their use |
| CN106795151B (zh) * | 2014-08-06 | 2021-05-07 | 诺华股份有限公司 | 蛋白激酶c抑制剂和它们的使用方法 |
| US11059804B2 (en) | 2014-08-06 | 2021-07-13 | Novartis Ag | Protein kinase C inhibitors and methods of their use |
| US11505541B2 (en) | 2014-08-06 | 2022-11-22 | Novartis Ag | Protein kinase C inhibitors and methods of their use |
| WO2021115335A1 (zh) * | 2019-12-09 | 2021-06-17 | 石药集团中奇制药技术（石家庄）有限公司 | 作为周期蛋白依赖性激酶9抑制剂的化合物及其应用 |
| CN114787142A (zh) * | 2019-12-09 | 2022-07-22 | 石药集团中奇制药技术（石家庄）有限公司 | 作为周期蛋白依赖性激酶9抑制剂的化合物及其应用 |
| CN114787142B (zh) * | 2019-12-09 | 2024-08-02 | 石药集团中奇制药技术（石家庄）有限公司 | 作为周期蛋白依赖性激酶9抑制剂的化合物及其应用 |
| CN115381824A (zh) * | 2021-05-24 | 2022-11-25 | 石药集团中奇制药技术（石家庄）有限公司 | 周期蛋白依赖性激酶9抑制剂的用途 |
| WO2022247796A1 (zh) * | 2021-05-24 | 2022-12-01 | 石药集团中奇制药技术（石家庄）有限公司 | 周期蛋白依赖性激酶9抑制剂的用途 |
| WO2022247785A1 (zh) * | 2021-05-24 | 2022-12-01 | 石药集团中奇制药技术（石家庄）有限公司 | 一种周期蛋白依赖性激酶9抑制剂的用途 |
| CN115381823A (zh) * | 2021-05-24 | 2022-11-25 | 石药集团中奇制药技术（石家庄）有限公司 | 一种周期蛋白依赖性激酶9抑制剂的用途 |
| CN115381824B (zh) * | 2021-05-24 | 2024-11-05 | 石药集团中奇制药技术（石家庄）有限公司 | 周期蛋白依赖性激酶9抑制剂的用途 |
| CN115381823B (zh) * | 2021-05-24 | 2024-11-05 | 石药集团中奇制药技术（石家庄）有限公司 | 一种周期蛋白依赖性激酶9抑制剂的用途 |
| CN115448874A (zh) * | 2021-06-09 | 2022-12-09 | 石药集团中奇制药技术（石家庄）有限公司 | 固体形式的周期蛋白依赖性激酶9抑制剂及其用途 |
| WO2022257965A1 (zh) * | 2021-06-09 | 2022-12-15 | 石药集团中奇制药技术（石家庄）有限公司 | 固体形式的周期蛋白依赖性激酶9抑制剂及其用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2012002758A (es) | 2012-04-19 |
| EP2473505A1 (en) | 2012-07-11 |
| CA2772265A1 (en) | 2011-03-10 |
| KR20120076352A (ko) | 2012-07-09 |
| AU2010291199A1 (en) | 2012-03-08 |
| US20120165306A1 (en) | 2012-06-28 |
| BR112012004836A2 (pt) | 2019-09-24 |
| IN2012DN01273A (enExample) | 2015-05-15 |
| WO2011026904A1 (en) | 2011-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102498107A (zh) | 作为激酶抑制剂的杂芳基化合物 | |
| CN102482265A (zh) | 用于治疗增殖性疾病的吡嗪基吡啶化合物 | |
| CN102471310A (zh) | 用于治疗增生性疾病的联吡啶化合物 | |
| JP5650735B2 (ja) | タンパク質キナーゼ調節剤としてのピリジンおよびピラジン誘導体 | |
| WO2012101064A1 (en) | N-acyl pyrimidine biaryl compounds as protein kinase inhibitors | |
| WO2012101063A1 (en) | N-acyl pyridine biaryl compounds and their uses | |
| TW202136241A (zh) | 用作抗癌劑的吡唑基衍生物 | |
| CN103339110A (zh) | 作为cdk9抑制剂的取代的杂-联芳基化合物及其用途 | |
| CN103298787A (zh) | 3-(氨基芳基)-吡啶化合物 | |
| TWI845638B (zh) | Ｅｅｄ及ｐｒｃ２調節劑之巨環唑并吡啶衍生物 | |
| WO2012101066A1 (en) | Pyridine biaryl amine compounds and their uses | |
| CN105189480A (zh) | 在治疗由IKKε和/或TBK-1机制介导的疾病中有用的嘧啶化合物 | |
| WO2012101065A2 (en) | Pyrimidine biaryl amine compounds and their uses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120530 |